SCHEMBL7944814

SCHEMBL7944814

Cc1ccc(C(=O)Nc2ccc(F)c(CNc3cccnc3N)c2)nc1

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
BACE1 P56817 14/20 0.52
BACE2 Q9Y5Z0 3/20 0.47
NPC1 O15118 1/20 0.43
RAB9A P51151 1/20 0.43
SMN1; SMN2 Q16637 1/20 0.43
GRM4 Q14833 1/20 0.41
HDAC3 O15379 3/20 0.40
HDAC1 Q13547 3/20 0.40
HDAC8 Q9BY41 2/20 0.40
HDAC2 Q92769 2/20 0.40
ABL1 P00519 1/20 0.40
PDGFRB P09619 1/20 0.40
KDR P35968 1/20 0.40
HDAC4 P56524 1/20 0.40
HDAC7 Q8WUI4 1/20 0.40
HDAC10 Q969S8 1/20 0.40
HDAC11 Q96DB2 1/20 0.40
HDAC6 Q9UBN7 1/20 0.40
HDAC9 Q9UKV0 1/20 0.40
HDAC5 Q9UQL6 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7945292 0.90 BACE1 (0.52) BACE1BACE2
SCHEMBL7943303 0.90 BACE1 (0.52) BACE1BACE2
SCHEMBL7941880 0.90 SMN1; SMN2 (0.57) BACE1BACE2NPC1RAB9ASMN1; SMN2
SCHEMBL7943356 0.89 BACE1 (0.51) BACE1NPC1RAB9ASMN1; SMN2GRM4
SCHEMBL7945289 0.89 BACE1 (0.50) BACE1BACE2
SCHEMBL7944850 0.88 BACE1 (0.56) BACE1BACE2AURKAAURKB
SCHEMBL7933218 0.88 BACE1 (0.50) BACE1BACE2NPC1RAB9ASMN1; SMN2
SCHEMBL12301454 0.87 BACE1 (0.51) BACE1BACE2NPC1RAB9ASMN1; SMN2
SCHEMBL7944846 0.87 BACE1 (0.49) BACE1BACE2GRM4
SCHEMBL7944835 0.86 BACE1 (0.54) BACE1BACE2NPC1RAB9ASMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110237576-A1 2-AMINOPYRIMIDIN-4-ONE AND 2-AMINOPYRIDINE DERIVATIVES BOTH HAVING BACE1-INHIBITING ACTIVITY SHIONOGI & CO., LTD. (JP) 2011-09-29 US disclosed
WO-2010047372-A1 2-AMINOPYRIDIN-4-ONE AND 2-AMINOPYRIDINE DERIVATIVE BOTH HAVING BACE1-INHIBITING ACTIVITY 塩野義製薬株式会社 (JP) 2010-04-29 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110237576-A1 2-AMINOPYRIMIDIN-4-ONE AND 2-AMINOPYRIDINE DERIVATIVES BOTH HAVING BACE1-INHIBITING ACTIVITY BACE1, APP, BACE2 BACE1 1/4885BACE2 3/4885NPC1 431/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.